Sanofi's dual-action biotech asthma drug performs well in test

November 11, 2014 9:58 AM

1 0

(Reuters) - An experimental biotech drug for moderate to severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting that its dual-action mechanism may be highly effective.

The encouraging data allows the companies to begin final-stage Phase III asthma trials on the medicine, which is also being developed for atopic dermatitis and chronic sinusitis with nasal polyps.

Also read: BRIEF-Hexagon CEO says work continues with "business as usual" after news of chairman stepping down

Read more

To category page